Regulation of interferon-γ production by IL-12 and IL-18

doi:10.1016/S0952-7915(98)80163-5

Current Opinion in Immunology

Volume 10, Issue 3, June 1998, Pages 259-264

https://doi.org/10.1016/S0952-7915(98)80163-5 Get rights and content

Abstract

IL-18 (interferon-inducing factor) and IL-12 exhibit a marked synergism in interferon-γ induction in T cells. Investigations into the mechanism of this synergism have revealed that IL-12 upregulates expression of the IL-18 receptor on cells producing interferon-γ. Although IL-18 does not induce the development of Th1 cells, it is essential for the effective induction and activation of Th1 cells by IL-12. As for natural killer cells, IL-18 seems to activate them independently of IL-12. Although IL-12 and IL-18 activate both innate and acquired immunity, their excessive production by activated macrophages may induce multiple organ disorders including disruption of the immune system.

References (44)

H Tsutsui et al.
IFN-γ-inducing factor upregulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones
J Immunol
(1996)
H Okamura et al.
A novel costimulatory factor for gamma interferon induction found in the liver of mice caused endotoxic shock
Infect Immun
(1995)
K Kuida et al.
Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice
Nature
(1996)
JF Bazan et al.
A newly defined interleukin 1?
Nature
(1996)
AS Baldwin
The NF-κB and IκB proteins: new discovery and insights
Annu Rev Immunol
(1996)
MJ Skeen et al.
Activation of γδ T cells for production of IFN-γ is mediated by bacteria via macrophage-derived cytokines IL-1 and IL-12
J Immunol
(1995)
NG Jacobson et al.
Interleukin 12 signaling in T helper type 1 (Th1) cells involves tyrosine phosphorylation of signal transducer and activation of transcription (STAT) 3 and STAT 4
J Exp Med
(1995)
H-J Ahn et al.
A mechanism underlying synergy between IL-12 and IFN-γ-inducing factor in enhanced production of IFN-γ
J Immunol
(1997)
V Pistoia et al.
In vitro production of interleukin 1 by normal and malignant human B lymphocytes
J Immunol
(1986)
C Gerard et al.
Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia
J Exp Med
(1993)

MA Farrar et al.

The molecular cell biology of interferon-γ and its receptor

Annu Rev Immunol

(1993)

U Boehm et al.

Cellular responses to interferon-γ

Annu Rev Immunol

(1997)

G Trinchieri

Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity

Annu Rev Immunol

(1995)

GJ Bancroft et al.

Natural immunity, a T cell-independent pathway of macrophage activation, defined in the SCID mouse

Immunol Rev

(1992)

H Okamura et al.

Cloning of a new cytokine that induces IFN-γ production by T cells

Nature

(1995)

T Dao et al.

Interferon-γ-inducing factor, a novel cytokine, enhances Fas ligand-mediated cytotoxicity of murine T helper 1 cells

Cell Immunol

(1996)

S Ushio et al.

Cloning of cDNA for human IFN-γ-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein

J Immunol

(1996)

MJ Micallef et al.

Interferon-γ-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon-γ production

Eur J Immunol

(1996)

K Kohno et al.

IFN-γ-inducing factor (IGIF) is a costimulatory factor on the activation of Th1, but not Th2 cells and exerts its effect independently of IL-12

J Immunol

(1997)

Y Gu et al.

Activation of interferon-γ-inducing factor mediated by interleukin-1β converting enzyme

Science

(1997)

T Ghayur et al.

Caspase 1 processes IFN-γ-inducing factor and regulates LPS-induced IFN-γ production

Nature

(1997)

J-I Henter et al.

Hypercytokinemia in familial hemophagocytic lymphohistocytosis

Blood

(1991)

Cited by (474)

Bioengineering strategies to enhance the interleukin-18 bioactivity in the modern toolbox of cancer immunotherapy
2024, Cytokine and Growth Factor Reviews
Cytokines are the first modern immunotherapeutic agents used for activation immunotherapy. Interleukin-18 (IL-18) has emerged as a potent anticancer immunostimulatory cytokine over the past three decades. IL-18, structurally is a stable protein with very low toxicity at biological doses. IL-18 promotes the process of antigen presentation and also enhances innate and acquired immune responses. It can induce the production of proinflammatory cytokines and increase tumor infiltration of effector immune cells to revert the immunosuppressive milieu of tumors. Furthermore, IL-18 can reduce tumorigenesis, suppress tumor angiogenesis, and induce tumor cell apoptosis. These characteristics present IL-18 as a promising option for cancer immunotherapy. Although several preclinical studies have reported the immunotherapeutic potential of IL-18, clinical trials using it as a monotherapy agent have reported disappointing results. These results may be due to some biological characteristics of IL-18. Several bioengineering approaches have been successfully used to correct its defects as a bioadjuvant. Currently, the challenge with this anticancer immunotherapeutic agent is mainly how to use its capabilities in a rational combinatorial therapy for clinical applications. The present study discussed the strengths and weaknesses of IL-18 as an immunotherapeutic agent, followed by comprehensive review of various promising bioengineering approaches that have been used to overcome its disadvantages. Finally, this study highlights the promising application of IL-18 in modern combinatorial therapies, such as chemotherapy, immune checkpoint blockade therapy, cell-based immunotherapy and cancer vaccines to guide future studies, circumventing the barriers to administration of IL-18 for clinical applications, and bring it to fruition as a potent immunotherapy agent in cancer treatment.
Emulsion and liposome-based adjuvanted R21 vaccine formulations mediate protection against malaria through distinct immune mechanisms
2023, Cell Reports Medicine
Adjuvanted protein vaccines offer high efficacy, yet most potent adjuvants remain proprietary. Several adjuvant compounds are being developed by the Vaccine Formulation Institute in Switzerland for global open access clinical use. In the context of the R21 malaria vaccine, in a mouse challenge model, we characterize the efficacy and mechanism of action of four Vaccine Formulation Institute adjuvants: two liposomal (LQ and LMQ) and two squalene emulsion-based adjuvants (SQ and SMQ), containing QS-21 saponin (Q) and optionally a synthetic TLR4 agonist (M). Two R21 vaccine formulations, R21/LMQ and R21/SQ, offer the highest protection (81%–100%), yet they trigger different innate sensing mechanisms in macrophages with LMQ, but not SQ, activating the NLRP3 inflammasome. The resulting in vivo adaptive responses have a different T_H1/T_H2 balance and engage divergent innate pathways while retaining high protective efficacy. We describe how modular changes in vaccine formulation allow for the dissection of the underlying immune pathways, enabling future mechanistically informed vaccine design.
Kidney bean protein hydrolysate as a fish meal replacer: Effects on growth, digestive enzymes, metabolic functions, immune-antioxidant parameters and their related gene expression, intestinal and muscular gene expression
2023, Aquaculture
A feeding trial for 70 days was designated on Nile tilapia, Oreochromis niloticus (O. niloticus). A total of 200 fish (34.38 ± 0.05 g) were assigned into five groups, four replicates for each (10 fish/replicate; 40 fish/group) and received five isonitrogenous and isocaloric diets with five replacement levels of fishmeal (FM) with kidney bean (Phaseolus vulgaris L) protein hydrolysate (KBH) (0, 25, 50, 75, 100%). The findings demonstrated a significant increase in the performance metrics (final body weight, total weight gain, average daily weight gain, protein efficiency ratio, and specific growth rate) with a considerable improvement in the feed conversion ratio across all replacement levels, with the greatest value obtained in the KBH75 and KBH100 groups. Regarding the broken line regression analysis, the optimum FM replacement level with KBH was 76%. By replacing FM with KBH, the growth hormone and digestive enzymes (amylase and protease) levels were significantly increased, whilst the glucose and leptin hormone levels significantly declined. The amino acid transporters (solute carrier family 15 member 2 and solute carrier family 26 member 6), insulin growth factor-1, the immune-associated genes (interleukin-8, toll-like receptors-7, and cc-chemokine), and the antioxidant-associated genes (glutathione peroxidase, superoxide dismutase, and Glutathione synthetase) expression was substantially boosted in all replacement levels, where the KBH50 group recorded the highest expression. As well as the mRNA expression of myostatin was down-turned in all replacement levels relative to the KBH0 group. Improving the immune functions (lysozyme, complement 3, nitric oxide, phagocytic %, and phagocytic index) was noticed by FM replacement with KBH. The cumulative mortality as a result of challenging with Aeromonas sobria at the end of the feeding trial was decreased by increasing the replacement level (80, 40, 37, 30, and 25% for KBH0, KBH25, KBH50, KBH75, and KBH100, respectively). From the economic point of view, the feed costs and feed cost/ kg gain declined in the KBH75 and KBH100 diets. From the aforementioned outcomes, KBH could replace the FM up to 100% with improving the growth and their related genes expression, digestive enzymes activity, and immune/antioxidant parameters and their encoding gene expression, and the optimal replacement level was 76%. The replacement of FM with KBH was economically efficient.
Single-cell RNA sequencing reveals the dynamics of hepatic non-parenchymal cells in autoprotection against acetaminophen-induced hepatotoxicity
2023, Journal of Pharmaceutical Analysis
Gaining a better understanding of autoprotection against drug-induced liver injury (DILI) may provide new strategies for its prevention and therapy. However, little is known about the underlying mechanisms of this phenomenon. We used single-cell RNA sequencing to characterize the dynamics and functions of hepatic non-parenchymal cells (NPCs) in autoprotection against DILI, using acetaminophen (APAP) as a model drug. Autoprotection was modeled through pretreatment with a mildly hepatotoxic dose of APAP in mice, followed by a higher dose in a secondary challenge. NPC subsets and dynamic changes were identified in the APAP (hepatotoxicity-sensitive) and APAP-resistant (hepatotoxicity-resistant) groups. A chemokine (C-C motif) ligand 2⁺ endothelial cell subset almost disappeared in the APAP-resistant group, and an R-spondin 3⁺ endothelial cell subset promoted hepatocyte proliferation and played an important role in APAP autoprotection. Moreover, the dendritic cell subset DC-3 may protect the liver from APAP hepatotoxicity by inducing low reactivity and suppressing the autoimmune response and occurrence of inflammation. DC-3 cells also promoted angiogenesis through crosstalk with endothelial cells via vascular endothelial growth factor-associated ligand-receptor pairs and facilitated liver tissue repair in the APAP-resistant group. In addition, the natural killer cell subsets NK-3 and NK-4 and the Sca-1^–CD62L⁺ natural killer T cell subset may promote autoprotection through interferon-γ-dependent pathways. Furthermore, macrophage and neutrophil subpopulations with anti-inflammatory phenotypes promoted tolerance to APAP hepatotoxicity. Overall, this study reveals the dynamics of NPCs in the resistance to APAP hepatotoxicity and provides novel insights into the mechanism of autoprotection against DILI at a high resolution.
Immunological profile of two canine breeds in an endemic region of Leishmania infantum
2023, Veterinary Parasitology: Regional Studies and Reports
Visceral leishmaniosis is the one of the most important protozoal zoonoses in Europe, and it is caused by Leishmania infantum, an intracellular protozoan parasite. The disease is endemic in dogs in the Mediterranean area. The main goal of this work is to correlate the levels of several cytokines linked to immune response against L. infantum infection in two canine breeds. Thirty-one Boxer and twenty-eight Ibizan Hound dogs living in the Valencian Community (East coast of Spain) were analyzed for the presence of anti-Leishmania antibodies in serum by IFAT test. Cytokines IFN-γ, TNF-α, IL-2, IL-6, IL-8, and IL-18 were determined by ELISA commercial tests. The levels of IFN-γ, IL-2, and IL-18 in our study, cytokines linked to a cellular immune response, were higher (p < 0.05) in the Ibizan Hound breed; IL-6 levels were higher, although not significant, and only levels of IL-8 were higher in Boxer than in Ibizan Hound. No expression of TNF-α was found. These results corroborate that Ibizan Hound can develop a protective response against canine leishmaniosis, while Boxer is a susceptible breed. The study of immunological aspects in the different canine breeds may represent a useful tool in the prediction of the disease.
Therapeutic treatment with phosphodiesterase-4 inhibitors alleviates kidney injury and renal fibrosis by increasing MMP-9 in a doxorubicin-induced nephrotoxicity mouse model
2023, International Immunopharmacology
Nephrotic syndrome (NS) is associated with kidney dysfunction and is an important cause of morbidity and mortality in industrialized countries. Here, we evaluated the effects of the phosphodiesterase-4 (PDE-4) inhibitors rolipram and roflumilast on a doxorubicin-induced NS model. Early-stage rolipram treatment preserved glomerular filtration barrier function, as indicated by reduced serum protein and albumin loss and the prevention of hypercholesterolemia. These effects were associated with reduced glomerular and tubular lesions and abrogated renal cell apoptosis. In addition, rolipram treatment reduced inflammation, which was characterized by a decrease in macrophage accumulation and reduced levels of CCL2 and TNF in the kidneys. Rolipram also reduced renal fibrosis, which was associated with decreased α-smooth muscle actin (α-SMA) area and increased metalloproteinase 9 (MMP9) activity in renal tissue. Late-stage rolipram or roflumilast treatment preserved glomerular filtration barrier function, as characterized by reduced serum albumin loss, decreased proteinuria, and the prevention of hypercholesterolemia. Importantly, only roflumilast treatment was associated with a reduction in glomerular and tubular lesions at this time point. In addition, both rolipram and roflumilast reduced renal tissue fibrosis and MMP9 activity in renal tissue.

View all citing articles on Scopus

View full text

Regulation of interferon-γ production by IL-12 and IL-18

Abstract

J Immunol

Infect Immun

Nature

Nature

Annu Rev Immunol

J Immunol

J Exp Med

J Immunol

J Immunol

J Exp Med

The molecular cell biology of interferon-γ and its receptor

Annu Rev Immunol

Cellular responses to interferon-γ

Annu Rev Immunol

Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity

Annu Rev Immunol

Natural immunity, a T cell-independent pathway of macrophage activation, defined in the SCID mouse

Immunol Rev

Cloning of a new cytokine that induces IFN-γ production by T cells

Nature

Interferon-γ-inducing factor, a novel cytokine, enhances Fas ligand-mediated cytotoxicity of murine T helper 1 cells

Cell Immunol

Cloning of cDNA for human IFN-γ-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein

J Immunol

Interferon-γ-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon-γ production

Eur J Immunol

IFN-γ-inducing factor (IGIF) is a costimulatory factor on the activation of Th1, but not Th2 cells and exerts its effect independently of IL-12

J Immunol

Activation of interferon-γ-inducing factor mediated by interleukin-1β converting enzyme

Science

Caspase 1 processes IFN-γ-inducing factor and regulates LPS-induced IFN-γ production

Nature

Hypercytokinemia in familial hemophagocytic lymphohistocytosis

Blood